Applied Therapeutics (NASDAQ:APLT – Get Free Report) and Immuron (NASDAQ:IMRN – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.
Valuation & Earnings
This table compares Applied Therapeutics and Immuron”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Applied Therapeutics | $1.00 million | 15.86 | -$105.62 million | ($0.10) | -1.03 |
| Immuron | $4.72 million | 1.91 | -$3.38 million | N/A | N/A |
Institutional & Insider Ownership
98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 7.0% of Immuron shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Applied Therapeutics and Immuron’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Applied Therapeutics | N/A | -340.84% | -175.00% |
| Immuron | N/A | N/A | N/A |
Volatility & Risk
Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Immuron has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Applied Therapeutics and Immuron, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Applied Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| Immuron | 1 | 0 | 0 | 0 | 1.00 |
Applied Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Immuron.
About Applied Therapeutics
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
About Immuron
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.
Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
